Lucence, the Diagnostics Development Hub (DxD Hub), and the National Cancer Centre Singapore (NCCS) have launched UNITED 2.0, a S$6 million research collaboration to develop a next-generation clinical-grade cancer profiling test using AI.

• Technical Approach: The project utilises dual Whole Exome Sequencing (WES) and Whole Transcriptome Sequencing (WTS) to provide comprehensive tumour profiling across DNA and RNA signals.
• Timeline and Scope: The three-year collaboration focuses on a broad range of cancers, including breast, lung, and colon, and intends to develop Minimal Residual Disease (MRD) tools for recurrence monitoring.
• Patient Integration: A Memorandum of Understanding (MOU) with the Brain Tumour Society Singapore (BTSS) has been established to incorporate patient perspectives into the research and development process.

This summary is based on a press release issued by Lucence, DxD Hub, and NCCS.